Presentation is loading. Please wait.

Presentation is loading. Please wait.

Stroke Prophylaxis Oral anticoagulation Lauren Butler

Similar presentations

Presentation on theme: "Stroke Prophylaxis Oral anticoagulation Lauren Butler"— Presentation transcript:

1 Stroke Prophylaxis Oral anticoagulation Lauren Butler
Dr Pervez Muzaffar

2 symptoms AF – most common arrhythmia Asymptomatic/exercise intolerance
chest pain/palpitation/fainting CCF/TIA weight loss/diarrhoea Light-headedness

3 Diagnosis History Examination (inc manual pulse check)
ECG (essential for diagnosis) Case specific bloods Echocardiogram Cxr

4 Classification Timing and termination based classification
1st detected - only one diagnosed episode Paroxysmal - recurrent self terminates < 7 days Persistent - recurrent lasts for > 7 days Permanent - on-going long term Other categories: Lone AF – age under 60 no h/o CVD/HT/Pulmonary disease Non-valvular AF – absence of Rheumatic MVD/prosthetic valve or MV repair Secondary AF – MI/cardiac surgery/pericarditis/myocarditis/hyperthyroidism/PE/Pneumonia

5 We need to improve Our prevalence of AF is below national average
1.12% BwD 1.74% England In BwD we only anticoagulate 42% of High risk AF cases, England 56%, we should aim for 85%!

6 Stroke in AF 14% of all strokes are due to AF
AF increases risk of stroke five-fold strokes per year occur in AF patients, of these are directly attributable to the AF AF strokes tend to be bigger and more disabling Warfarin reduces stroke risk by around 2/3

7 Atrial fibrillation (AF) Points Pay stage
AF1. The practice can produce a register of patients with atrial fibrillation 5 AF5. The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHADS2 risk stratification scoring system in the preceding 15 months (excluding those whose previous CHADS2 score is greater than 1) 10 40–90 % AF6. In those patients with atrial fibrillation in whom there is a record of a CHADS2 score of 1(latest in the preceding 15 months), the percentage of patients who are currently treated with anti-coagulation drug therapy or anti-platelet therapy 6 50-90% AF7. In those patients with atrial fibrillation whose latest record of a CHADS2 score is greater than 1, the percentage of patients who are currently treated with anti-coagulation therapy 40-70%

8 Capturing information
Grasp tool- how does it work? Works on all GP software Set of MIQUEST queries on AF patients Calculates stroke risk using CHADS2 With option to use latest CHA2DS2-VASc scoring tool Highlights those who would benefit from a medication review Does not assess C/I to warfarin Results in spread sheet/dashboard format


10 Classic Grasp-AF tool view

11 CHADS2 Score Congestive Heart failure 1 Hypertension 1 Age ≥ 75 1
Diabetes Previous Stroke or TIA Consider anticoagulation if ≥ 2 Use CHA2DS2VASc assessment tool if < 2

12 Yet under prescribed NICE estimate that approximately 40% of patients in whom warfarin is indicated are not receiving it. RCPE % of people with AF should be considered for this treatment

13 Aspirin vs. Warfarin Warfarin represents a 64% reduced stroke risk
BAFTA - Warfarin did not increase haemorrhage risk in comparison with aspirin (Warfarin 1.4% Aspirin 1.6%) Falls - Older patients taking warfarin must fall about 295 times in one year for warfarin not to be optimal therapy and the propensity to fall is not a contraindication to the use of antithrombotic agents (especially warfarin) in elderly persons with AF. NB current guidance suggests that Aspirin should not be used for stroke prevention in AF. (RCPE UK 2012)

14 CHA2DS2-VASc Score Congestive Heart Failure/ LVD 1 Hypertension 1
Age ≥ 75 years Diabetes mellitus Stroke/TIA/TE Vascular disease (MI, PAD or aortic plaque) Age between 65 and 74 year Sc - Sex category - Female Score of ≥ 2 anticoagulation therapy Score of 1 consider risk/benefit and HAS-BLED score to aid decision for anticoagulation or antiplatelet therapy

15 HAS-BLED Score Annual Hypertension, Uncontrolled Sys >160mmHg 1pt Abnormal Kidney (Cr > 200) and/or liver function 1pt each Stroke pt Bleeding, previous history, anaemia or predisposition 1pt Labile INR, high INR or poor time in Therapeutic range 1pt Elderly, age ≥ 65yrs 1pt Drugs and/or alcohol, antiplatelets, more than drinks per week pt each A score of 3 or more is not a contraindication to oral anticoagulation but these patients require extra care

16 CHADS 2 vs HAS – BLED Risk score Risk score
0 1.9% 1 2.8% 2 4.0% 3 5.9% 4 8.5% 5 12.5% 6 18.2% 0 1.1% % % % % %

17 Using both….. Lancashire & Cumbria Guidelines
Calculate CHADS2 score ……… CHADS2 > 1 anti-coagulate CHADS2 ≤ 1 calculate CHA2DS2-VASC CHA2DS2-VASC >1 anti-coagulate CHA2DS2-VASC ≤1no treatment (or aspirin) Consider a risk of bleeding assessment such as the HAS-BLED score before anticoagulation

18 New oral anticoagulant drugs
Dabigatran, RivaroXaban, ApiXaban Dabigatrin (Pradaxa ) 150mg bd or 110 mg bd Rivaroxaban (Xarelto ) 20mg od Apixaban 5mg bd (not yet licensed for stroke prevention in AF) NOACs are recommended as an treatment option where warfarin is either contraindicated or where the patient has a documented hypersensitivity to or intolerance of coumarin anticoagulants severe enough to cause treatment withdrawal Studies show similar or better efficacy than warfarin with less risk of bleeding No monitoring required Few drug and diet interactions Very expensive (but savings on monitoring)

19 New oral anticoagulant drugs (2)
Still black triangle drugs – Amber rating in BwD No simple antidote (but short half life) In RE-LY trial, Dabigatran higher drop out rate than warfarin Higher rate of GI bleeding, lower rate of ICH Warfarin is still likely to remain drug of choice for those who are well controlled (TTR 65%) However NOACs do have advantages, and will benefit a proportion of the population

20 Warfarin or NOAC ? Where to refer ?
Warfarin Anticoag clinic NOAC Community cardiology (Mammen) Remember – NOACs still carry bleeding risk, black triangle drugs with no antidote

21 Key points Aspirin is ineffective in stroke prevention for AF
If warfarin can not be controlled and compliance is not the issue then a NOAC should be commenced Where compliance is the issue, then is it preferable to at least be able to monitor this? Watch NOACs in the elderly and those with poor renal function Remember – BwD anticoag service has domiciliary service for patients unable to attend clinic

22 case 66 years old female presented with sob/tiredness feels skipping beat occasionally when playing golf no cough no chest pain no fainting no other symptoms PMH: nil No allergy

23 Examination/tests BP 132/70 pulse 104/min irregular no murmur no ankle oedema no carotid bruits CNS- normal Chest- sats 98% RR 20/min no wheeze mild basal crepts apyrexial ECG AF 112/min Requested bloods

24 Diagnosis? CHADS2 Score?? What would you next?

25 Anticoagulate? CHA2DS2-VASc Score ?? What is next?

26 NOAC After discussion she decides to be referred to anticoagulation clinic She comes back in a week time with her consultant surgeon son who says he does not want her to go on warfarin – but like her to go on Dabigatran (NOAC) Your response to his request? He wishes to pay for private prescription?

Download ppt "Stroke Prophylaxis Oral anticoagulation Lauren Butler"

Similar presentations

Ads by Google